新型化合物作为NLRP3抑制剂用于治疗喘或COPD
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
开发了抑制NLRP3 (NLR家族pyrin域含有3) 的新化合物. 这些化合物显示出治疗炎症性呼吸道疾病的潜力,如喘和慢性阻塞性肺病 (COPD).
科学领域:
- 药用化学 医学化学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- NLRP3炎症酶是炎症反应的关键调解者.
- NLRP3炎症酶的失调与喘和COPD等呼吸道疾病有关.
- 针对NLRP3为这些疾病提供了潜在的治疗策略.
研究的目的:
- 发现和描述抑制NLRP3.3活性的新型小分子.
- 评估这些NLRP3抑制剂在喘和COPD的治疗潜力.
主要方法:
- 新型化学实体的合成.
- 在体外测试以评估NLRP3抑制.
- 在体内研究以评估疾病模型中的疗效.
主要成果:
- 强效和选择性NLRP3抑制剂的鉴定.
- 在喘和COPD的临床前模型中证明治疗疗效.
- 建立合成路径用于化合物制备.
结论:
- 新的NLRP3抑制剂已经成功开发出来.
- 这些化合物代表了喘和COPD的有前途的治疗药物.
- 这些发现支持进一步开发针对呼吸道炎症的NLRP3向疗法.
更多相关视频
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
12:27The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
Published on: April 2, 2014
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
COPD: Management Using Bronchodilators and Corticosteroids
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications
